首頁 > 市場調查報告書 > 製藥

感染疾病

碳青黴烯類抗生素市場規模、佔有率和成長分析：按藥物、適應症、通路、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2078331

碳青黴烯類抗生素市場規模、佔有率和成長分析：按藥物、適應症、通路、最終用戶和地區分類－2026-2033年產業預測

Carbapenem Based Antibiotics Market Size, Share, and Growth Analysis, By Drug, By Indication (Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections), By Distribution, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年06月30日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球碳青黴烯類抗生素市場價值為 18.2 億美元，預計到 2033 年將從 2025 年的 19.1 億美元成長至 28.5 億美元，預測期（2026-2033 年）的複合年成長率為 5.12%。

全球碳青黴烯類抗生素市場涵蓋了Imipenem、Meropenem、厄他培南和多利培南等領先藥物，主要針對多重抗藥性革蘭氏陰性病菌感染。由於產超頻譜BETA-內醯胺酶（ESBL）病原體的激增限制了基礎治療的療效，臨床醫師對頻譜替代藥物的需求推動了該市場的成長。醫院藥物使用方案優先考慮對重症患者使用碳青黴烯類抗生素，這影響了醫療預算。此外，為對抗耐碳青黴烯腸桿菌科細菌（CRE），對聯合治療的需求不斷成長，也推動了市場擴張，因為醫生擴大將碳青黴烯類抗生素與BETA-內醯胺酶抑製劑聯合使用。人工智慧驅動的藥物發現技術的進步透過加速識別新標靶和最佳化治療方案，進一步擴大了該市場。這確保了即使抗生素抗藥性挑戰日益嚴峻，也能持續獲得有效的治療方案，並刺激了研發投入的增加。

全球碳青黴烯類抗生素市場的成長要素

全球碳青黴烯類抗生素市場正受到醫院內多重抗藥性感染疾病發生率上升的顯著推動，促使臨床醫師越來越依賴這些強效治療方案。這種依賴的增加源於對有效控制嚴重感染疾病的迫切需求，導致處方率上升，尤其是在急診環境中。隨著醫療專業人員努力降低治療失敗的風險，碳青黴烯類抗生素的生產和分銷也不斷擴大。這一趨勢不僅推動了整體市場成長，也凸顯了碳青黴烯類抗生素在改善治療方案和患者預後方面的關鍵作用。

全球碳青黴烯類抗生素市場的限制因素

全球碳青黴烯類抗生素市場面臨諸多限制因素，主要原因在於其高成本。高成本源自於複雜的生產流程和嚴格的監管標準。對於醫療機構而言，尤其是資源匱乏的醫院和新興市場，高昂的價格構成了巨大的財務挑戰，因為這些地區的預算限制會顯著影響採購決策。因此，臨床醫生可能傾向於選擇療效相當但價格較低廉的替代療法，這限制了市場成長。此外，這種經濟負擔也會影響門診患者的用藥依從性，進而降低公立和私立醫療系統對碳青黴烯類抗生素的整體需求。

全球碳青黴烯類抗生素市場趨勢

全球碳青黴烯類抗生素市場呈現顯著上升趨勢，這主要得益於醫院和實驗室抗藥性監測活動的快速擴展。醫療機構正透過採用先進的基因測序和即時數據平台，有效監測碳青黴烯抗藥性菌的出現。這種預防性方法有助於及時調整經驗性治療方案，從而減少不必要的碳青黴烯類藥物使用，並加強社區抗菌藥物管理工作。基於這些認知，製藥公司正致力於開發針對特定抗藥性機制的新型候選藥物，從而導致對現有碳青黴烯類藥物以及能夠應對不斷演變的抗藥性模式的創新藥物的需求增加。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Merck & Co.（Primaxin/Imipenem）
AstraZeneca（Merrem/Meropenem）
Pfizer Inc.
Johnson & Johnson（Doribax）
Shionogi & Co.
Daiichi Sankyo
Fresenius Kabi
Pfizer（Tienam）
Sun Pharmaceutical
Teva Pharmaceutical
Dr. Reddy's Laboratories
Hikma Pharmaceuticals
Mylan（Viatris）
Cipla Ltd.
Aurobindo Pharma
Lupin Limited
Amneal Pharmaceuticals
Glenmark Pharmaceuticals
Zydus Cadila
Sandoz（Novartis）

結論與建議

簡介目錄

Product Code: SQMIG35I2856

Global Carbapenem Based Antibiotics Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 1.91 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 5.12% during the forecast period (2026-2033).

The global carbapenem-based antibiotics market features key drugs such as imipenem, meropenem, ertapenem, and doripenem, primarily targeting multidrug-resistant Gram-negative infections. This market's growth is driven by the increasing prevalence of extended-spectrum B-lactamase (ESBL) producing pathogens that limit the efficacy of first-line treatments, leading clinicians to seek broader-spectrum alternatives. Hospital stewardship programs prioritize carbapenems for severe cases, influencing healthcare budgets. The rising demand for combination therapies to combat carbapenem-resistant Enterobacteriaceae (CRE) reinforces market expansion, as physicians increasingly pair carbapenems with B-lactamase inhibitors. Advances in AI-driven drug discovery further enhance this market by expediting the identification of new targets and optimizing treatment regimens, ensuring a sustained pipeline of effective therapies amid rising resistance challenges and fostering greater research investment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Carbapenem Based Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Carbapenem Based Antibiotics Market Segments Analysis

Global carbapenem based antibiotics market is segmented by drug, indication, distribution, end-user and region. Based on drug, the market is segmented into Imipenem-Cilastatin, Meropenem, Ertapenem, Doripenem and Biapenem. Based on indication, the market is segmented into Hospital-Acquired Pneumonia (HAP), Complicated Intra-Abdominal Infections and Septicemia. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Hospitals (ICU) and Specialty Infectious Disease Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Carbapenem Based Antibiotics Market

The global market for carbapenem-based antibiotics is being significantly propelled by the rising incidence of multidrug-resistant bacterial infections within hospital settings, leading clinicians to increasingly depend on these powerful treatment options. This growing reliance emerges from the urgent need for effective solutions to manage severe infections, resulting in heightened prescription rates, particularly in acute care environments. As medical professionals aim to reduce the risk of therapeutic failures, the market is responding with enhanced production and distribution of carbapenem antibiotics. This trend not only drives overall market growth but also underscores the critical role of carbapenems in improving treatment protocols and patient outcomes.

Restraints in the Global Carbapenem Based Antibiotics Market

The global market for carbapenem-based antibiotics faces significant constraints primarily due to their high costs, which stem from intricate manufacturing processes and strict regulatory standards. These elevated prices present a substantial financial challenge for healthcare providers, particularly in resource-limited hospitals and emerging markets where budgetary constraints heavily influence procurement decisions. As a result, clinicians may turn to more affordable alternative therapies that offer similar efficacy, limiting market growth. Additionally, the financial burden affects patient adherence to outpatient treatments, reducing overall demand for carbapenem-based therapies across both public and private healthcare systems.

Market Trends of the Global Carbapenem Based Antibiotics Market

The global market for carbapenem-based antibiotics is witnessing a significant upward trend driven by the rapid expansion of resistance surveillance initiatives in hospitals and laboratories. By adopting advanced genomic sequencing and real-time data platforms, healthcare providers are effectively monitoring the rise of carbapenem-resistant organisms. This proactive approach allows for timely adjustments in empiric therapy, curbing unnecessary carbapenem usage and enhancing regional antimicrobial stewardship efforts. Pharmaceutical companies are responding to these insights by focusing on the development of new candidates targeting specific resistance mechanisms, leading to increased demand for both established carbapenem products and innovative agents capable of combatting evolving resistance patterns.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Carbapenem Based Antibiotics Market Size by Drug & CAGR (2026-2033)

Market Overview
Imipenem-Cilastatin
Meropenem
Ertapenem
Doripenem
Biapenem

Global Carbapenem Based Antibiotics Market Size by Indication & CAGR (2026-2033)

Market Overview
Hospital-Acquired Pneumonia (HAP)
Complicated Intra-Abdominal Infections
Septicemia

Global Carbapenem Based Antibiotics Market Size by Distribution & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Specialty Pharmacies

Global Carbapenem Based Antibiotics Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals (ICU)
Specialty Infectious Disease Centers

Global Carbapenem Based Antibiotics Market Size & CAGR (2026-2033)

North America (Drug, Indication, Distribution, End-User)
- US
- Canada
Europe (Drug, Indication, Distribution, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug, Indication, Distribution, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug, Indication, Distribution, End-User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Drug, Indication, Distribution, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Merck & Co. (Primaxin/Imipenem)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (Merrem/Meropenem)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (Doribax)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shionogi & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (Tienam)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan (Viatris)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments